Aspirin Therapy Risks

Gastrointestinal Effects

Aspirin is associated with significant gastrointestinal bleeding risks with an odds ratio of 1.59 (95% CI 1.32-1.91), which should be carefully considered before initiating therapy, especially in high-risk patients 1
The most commonly reported adverse effects of aspirin are nonspecific gastrointestinal symptoms, including abdominal pain, dyspepsia, nausea, and vomiting 1
Gastrointestinal bleeding is the most common serious adverse event, with an increase of 0.29 events per 1,000 person-years of aspirin exposure 1
The risk of GI bleeding is dose-dependent, with higher doses associated with increased risk 2

Intracranial bleeding is associated with aspirin use (OR = 1.27; 95% CI 0.98-1.66), with an absolute risk increase of 0.1 events per 1,000 person-years 1
Bleeding events correlate with dose and increasing age 1
The estimated adjusted incidence rate ratio for major bleeding events increases by 1.05 (95% CI 1.05-1.05) with each year of age 1
Men have twice the risk for serious gastrointestinal bleeding compared to women 2

For GI symptoms and prophylaxis for bleeding, clinical management may include co-administration of a proton pump inhibitor (PPI) or H2 blocker 1
Use the lowest effective dose of aspirin (approximately 75-81 mg/day) as it seems as effective as higher dosages while potentially reducing side effects 2
Regular monitoring for signs of bleeding is recommended, especially in high-risk patients 1
Patients should be educated about signs and symptoms of GI bleeding (dark stools, vomiting blood, bright red blood per rectum, syncope, lightheadedness) 2

The American College of Cardiology recommends aspirin for secondary prevention of cardiovascular events in patients with a history of ischemia, despite a history of GI bleeding, with mandatory concurrent proton pump inhibitor (PPI) therapy to mitigate bleeding risk 3

Aspirin provides a greater benefit than risk for secondary prevention in patients with documented ischemia, and is strongly recommended, with a reduction in serious vascular events by 12% (relative risk 0.88, 95% CI 0.82-0.94) 3
Long-term aspirin therapy in high-risk vascular patients prevents 36-50 major vascular events per 1,000 patients treated, representing a 20-25% proportional risk reduction 4

Patients with a history of upper GI bleeding who require aspirin must receive concurrent PPI therapy, with omeprazole 20mg daily or equivalent PPI prescribed concurrently with aspirin initiation 5, 6
The use of the lowest effective aspirin dose (81mg daily) reduces GI bleeding risk without additional cardiovascular benefit 6, 3
Testing for and eradicating Helicobacter pylori if present further reduces bleeding risk in aspirin users, with recurrent bleeding rates of only 1.9% in patients with prior ulcer bleeding who took low-dose aspirin for 6 months 6

Aspirin should not be withheld in secondary prevention due to bleeding history alone, as the cardiovascular mortality benefit outweighs bleeding risk when proper gastroprotection is used 3
Enteric-coated or buffered aspirin should not be used to reduce GI bleeding risk, as studies show similar or higher relative risks compared to plain aspirin 6
Clopidogrel should not be substituted for aspirin in this scenario, as it carries similar or higher GI bleeding risk compared to aspirin plus PPI 6

In patients with acute per‑rectal bleeding while on aspirin, obtain a complete blood count, coagulation profile, renal function tests, and type‑and‑cross‑match blood products; assess hemodynamic stability and begin intravenous fluid resuscitation as needed. European Society of Cardiology recommends this initial work‑up for gastrointestinal hemorrhage. 7

Patients with a prior ischemic stroke are classified as very high cardiovascular risk; continuation of low‑dose aspirin (75‑81 mg daily) is essential for secondary stroke prevention because it markedly reduces major vascular events and mortality, outweighing the bleeding risk when gastro‑protection is used. American Heart Association/American Stroke Association guidelines support aspirin as the cornerstone antiplatelet therapy in this population. [8][9]

After definitive control of the bleeding source, aspirin should be restarted at the lowest effective dose (75‑81 mg daily) with mandatory concurrent proton‑pump inhibitor therapy (e.g., omeprazole 20 mg daily or equivalent) to mitigate recurrent gastrointestinal bleeding. This combined strategy is endorsed by the European Society of Cardiology. 10

Target blood pressure should be maintained below 140/90 mmHg in aspirin‑treated patients, because uncontrolled hypertension independently increases the risk of gastrointestinal bleeding. European Society of Cardiology recommends this blood‑pressure goal as part of bleeding‑risk reduction. 11